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Abstract
Introduction: Cannabis is listed as a Schedule I substance under the Controlled Substances Act of 1970,
meaning the US federal government defines it as an illegal drug that has high potential for abuse and no
established medical use; however, half of the states in the nation have enacted ‘‘medical marijuana’’ (MM)
laws. Clinicians must be aware of the evidence for and against the use of MM in their patients who may
consider using this substance.
Methods: A PubMed database search was performed using the text string: ‘‘Cannabis’’[Mesh] OR
‘‘Marijuana Abuse’’[Mesh] OR ‘‘Medical Marijuana’’[Mesh] OR ‘‘Marijuana Smoking’’[Mesh] OR ‘‘cannabi*’’
OR ‘‘tetrahydrocannabinol.’’ The search was further limited to randomized clinical trial publications in
English on human subjects to identify articles regarding the therapeutic use of phytocannabinoids for
psychiatric and neurologic disorders. Commercially available products (ie, dronabinol, nabilone, nabiximols)
and synthetic cannabinoids were excluded from the review.
Results: Publications were identified that included patients with dementia, multiple sclerosis, Parkinson
disease, Huntington disease, schizophrenia, social anxiety disorder, depression, tobacco use disorder, and
neuropathic pain.
Discussion: There is great variety concerning which medical conditions are approved for treatment with MM
for either palliative or therapeutic benefit, depending on the state law. It is important to keep an evidence-
based approach in mind, even with substances considered to be illegal under US federal law. Clinicians must
weigh risks and benefits of the use of MM in their patients and should ensure that patients have tried other
treatment modalities with higher levels of evidence for use when available and appropriate.
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Introduction
Although medical marijuana (MM) laws1 have been
enacted in half of the United States, marijuana is still
classified as a Schedule I substance under the Controlled
Substances Act of 1970. Schedule I substances are
considered to have a high potential for abuse and no
established medical use. Clinicians must be aware of the
evidence for and against the use of MM in their patients
who ask for authorization to use this substance. When
reviewing evidence it is important to take into account
what formulation was studied because outcomes have
varied considerably based on this factor alone. Some
studied forms of MM included oral cannabis extract (OCE),
which is typically a pill or capsule made by extracting
phytocannabinoids (eg, D-9-tetrahydrocannabinol [D-9-
THC] and cannabidiol [CBD]) from whole-plant cannabis,
vaporized or smoked cannabis (cannabinoids are ex-
pressed in terms of % concentration), synthetic THC (ie,
dronabinol), and other commercially available products
Q 2017 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. This is an
open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which
permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
(eg, nabiximols, which is a sublingual form of OCE
containing THC and CBD). It is important to mention that
some states only allow for certain formulations of MM to
be dispensed (eg, New York state only allows for OCE and
oil for vaporization, whereas other state laws allow for the
purchase of whole-plant cannabis).2 Notably, onset of
action varies substantially depending on route of admin-
istration and dosage form; intravenous administration and
inhalation have the fastest onset of action and greatest
bioavailability, oral administration is subject to first-pass
metabolism and reduced bioavailability, and oromucosal
routes reduce first-pass metabolism, which increases
bioavailability.3
Methods
A PubMed database search was performed using the text
string: ‘‘Cannabis’’[Mesh] OR ‘‘Marijuana Abuse’’[Mesh]
OR ‘‘Medical Marijuana’’[Mesh] OR ‘‘Marijuana Smo-
king’’[Mesh] OR ‘‘cannabi*’’ OR ‘‘tetrahydrocannabinol.’’
The search was further limited to randomized clinical trial
publications in English on human subjects to identify
articles regarding the therapeutic use of phytocannabi-
noids for psychiatric and neurologic disorders. Commer-
cially available products and synthetic cannabinoids were
excluded from the review because they are reviewed
elsewhere and are unique, patented formulations only
available in specific dosage forms.4 The initial search
returned 1507 publications (titles/abstracts of which were
reviewed by the author), of which 23 were identified for
inclusion based on the criteria outlined above. If a disease
state had only one negative published trial, it was included
in the Table but excluded from the results.
Results
Multiple Sclerosis
Multiple sclerosis (MS) is the only disease state discussed
herein for which there is an approved, commercially
available product (SativexW [nabiximols]), which is
marketed in 15 countries outside of the United States—
studies using this formulation were not included in this
review; however, many noncommercial formulations have
been evaluated. Small, double-blind, placebo-controlled
trials suggested benefit for spasticity based on subjective
ratings, which allowed for more rigorous work.5-8
The Cannabinoids in MS (CAMS) study (n¼630), the first
large trial of MM for MS, was a multicenter, randomized,
15-week, double-blind, placebo-controlled trial comparing
OCE to dronabinol and placebo.9 The primary outcome of
the study was change in spasticity as rated by the
Ashworth Scale score; notably, this scale is no longer
recommended for spasticity assessment.9 Results showed
that the difference in mean reduction of the Ashworth
Scale was not significant for either active treatment
versus placebo. Various secondary outcomes were as-
sessed (Table). The only outcome that reached statistical
significance was patient-reported measures of spasticity,
pain, sleep, and spasms. The authors point out that some
patients and doctors became unmasked in the active
treatment groups, but the assessors did not. This study
suggested that some patient-reported benefits may be
seen after 15 weeks of therapy, keeping in mind that these
were subjective data being reported by potentially
unmasked patients.
A randomized, double-blind, placebo-controlled, cross-
over study was conducted in 57 patients at a rehabilitation
center in Switzerland.10 The study compared OCE to
placebo, which were dosed up to 12 capsules per day,
divided to 3 times per day. Similar to the CAMS study, the
primary outcome was the total Ashworth Scale score.
There were numerous secondary outcomes. Results
showed that there was no statistically significant differ-
ence in primary or secondary outcome measures for the
intention-to-treat analysis set. For the 37 patients who
completed the study per protocol (ie, 90% adherence),
improvements in spasm frequency (P¼.013) and in
mobility (P¼.01) were seen after excluding 1 patient
who fell in the placebo phase of the study.
A 12-month follow-up to the CAMS study was also
completed.11 Ashworth Scale score reductions from
baseline to end point were 1.82 (95% confidence interval
[CI], 0.53 to 3.12) for dronabinol, 0.10 (95% CI, 0.99 to
1.19) for OCE, and 0.23 (95% CI, 1.41 to 0.94) for
placebo; P¼.04. Although statistical significance was
realized only for the dronabinol group, the clinical
significance of this finding remains unclear. There were
no significant findings regarding any secondary outcome.
Objective benefits were only observed for the dronabinol
group, but the study suggested that patient-reported
benefits of OCE may be maintained for up to 1 year.
All patients who were recruited for the original CAMS
study were assessed for urge incontinence episodes.12 The
primary outcome was a reduction in urge incontinence
episodes based on a 3-day urinary diary. Oral cannabis
extract reduced urge incontinence episodes by 25%
(P¼.005) and dronabinol by 19% (P¼.039) relative to
placebo. Although there was a lack of improvement in
bladder function in the main CAMS study, this publication
suggested that cannabinoids may have a clinical effect on
lower urinary tract symptoms.
The MS and Extract of Cannabis trial (n¼279) was a
multicenter, randomized, 12-week, double-blind, placebo-
controlled study comparing OCE to placebo.13 The study
was a follow-up to the CAMS study, and the primary
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outcome was an 11-point category rating scale to measure
perceived change in muscle stiffness from baseline to end
point, where 0¼ very much better, 5¼no difference, and
10¼ very much worse. A clinically relevant response to
the medication, or ‘‘relief of muscle stiffness,’’ was
defined as a category rating scale score of 0 to 3. Multiple
secondary outcomes were assessed (Table). Results
showed that 29.4% of patients on OCE achieved ‘‘relief
of muscle stiffness’’ versus 15.7% of patients on placebo
(OR, 2.26; 95% CI, 1.24 to 4.13; P¼.004).
Parkinson Disease
The first randomized, double-blind, placebo-controlled
trial of OCE in Parkinson disease (PD) was a 10-week
crossover study of 18 patients with levodopa-induced
dyskinesia.14 Primary outcome was the Unified Parkin-
son’s Disease Rating Score (UPDRS) questions 32 to 34
(pertaining to dyskinesias) score sum change from
baseline to end point. There was no significant difference
between active medication and placebo on the primary or
secondary outcomes. Notably, 71% of patients correctly
identified treatment.
Another randomized, double-blind, placebo-controlled
trial of OCE in PD was a 6-week study of 21 patients
that compared CBD 75 mg and CBD 300 mg to placebo.15
Outcome measures in this study were the UPDRS, the
Parkinson Disease Questionnaire-39 (PDQ-39—a validated
self-rated scale that provides a detailed look at clinically
significant outcomes like mobility, activities of daily living,
emotional well-being, stigma, social support, cognition,
communication, and physical discomfort), and the Udvalg
for Kliniske Undersøgelser side effect rating scale. There
were no differences on the UPDRS or the Udvalg for
Kliniske Undersøgelser side effect rating scale between
the active treatment groups and placebo. Significance was
realized on the PDQ-39 total score, which saw a
significantly greater change on CBD 300 mg versus
placebo (P¼.05).
Social Anxiety Disorder
A preliminary double-blind, placebo-controlled crossover
study comparing a single dose of CBD (400 mg) to placebo
was conducted in 10 treatment-naive men with general-
ized social anxiety disorder who were ages 20 to 33 years
and without comorbid psychiatric disorders.16 The single-
photon emission computed tomography (SPECT) imaging
procedure was used as the anxiety-provoking stimulus.
Participants rated their anxiety using the Visual Analogue
Mood Scale (VAMS). The VAMS in this study consisted of
16 items, grouped into 4 factors (ie, anxiety, mental
sedation, physical sedation, and ‘‘other feelings/atti-
tudes’’) and was measured at 30 minutes (predrug), 0
minutes (dosing time and prestress), 60 minutes (venous
cannula insertion), 75 minutes (pre-SPECT), and 140
minutes (poststress). Results showed that CBD signifi-
cantly reduced VAMS scores versus placebo on the anxiety
factor at times 60, 75, and 140 minutes (P , .001).
Measures of physical sedation, mental sedation, and
‘‘other feelings/attitudes’’ in patients on CBD were not
significantly different from those on placebo; this speaks
to the lack of appreciable side effects of CBD in this
patient population. In addition, this study showed that
CBD had a significant effect on increased brain activity in
the right posterior cingulate cortex (measured by Tc-ECD
SPECT imaging; P , .001), which is thought to be involved
in the processing of emotional information.
Another study17 investigating the use of CBD was
conducted in treatment-naive patients with social anxiety
disorder (n¼24). The patients were randomized to
receive either CBD 600 mg (n¼ 12) or placebo (n¼ 12)
prior to a Simulated Public Speaking Test (SPST). The
SPST, an experimental model for anxiety induction, is
thought to have predictive validity in social anxiety
disorder because fear of public speaking is a hallmark
feature of the illness. The two groups received active
treatment or placebo 1.5 hours before the SPST began;
measurements on the VAMS and Negative Self-State-
ments during Public Speaking scale (SSPS-N) were taken
over the course of the SPST in all 3 groups. The VAMS was
employed to measure anxiety, sedation (ie, mental
sedation), cognitive impairment (ie, physical sedation),
and discomfort (ie, ‘‘other feelings/attitudes’’). The CBD
group had significantly lower scores than the placebo
group during the speech (S) phase on the VAMS anxiety
(P¼.012), cognitive impairment (P¼.009), and discomfort
(P¼.029) factors. The VAMS sedation factor score was
significantly lower on CBD versus placebo at the
anticipatory (A) phase (P¼.016). Regarding the SSPS-N,
comparisons showed significant differences between CBD
and placebo at the A phase (P¼.043) and during the S
phase (P¼.001). Some have suggested that CBD’s
anxiolytic action may be mediated by the 5-HT1A
receptors, because it was shown to displace the agonist
[3H]8-OHDPAT from cloned human receptors in a
concentration-dependent manner; CBD also acts at an
agonist at 5-HT1A in signal transduction studies.
18
Schizophrenia
The first study19 of using THC in patients with schizo-
phrenia was a 3-day, randomized, double-blind, placebo-
controlled study of intravenous THC (doses 2.5 and 5 mg)
versus placebo. Patients were stable and were currently
taking antipsychotic medication. Results showed that THC
significantly increased learning and recall deficits, positive
and negative symptoms, general psychopathology, per-
ceptual alterations, akathisia, rigidity, dyskinesia, deficits
in vigilance, and plasma prolactin and cortisol levels. The
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TABLE: Randomized trials of medical marijuana in psychiatric and neurologic disorders
Study or
Condition/Source,
y
No. of
Participants
Cannabinoid
Formulation/Dose Outcomes Results/Conclusion
CAMS Study/
Zajicek et al,9
2003
630 OCE (D9-THC 2.5 mg/
CBD 1.25 mg per
capsule) versus
dronabinol (synthetic
D9-THC 2.5 mg per
capsule) versus
placebo
Primary: Change in spasticity
measured by the Ashworth
Scale
For both active medication
groups, significant
improvements were only
seen in the subjective
‘‘category’’ rating scales of
spasticity, pain, sleep, and
spasms. This study
suggested that some
patient-reported benefits
may be seen after 15 weeks
of therapy.
(Weight-based dosing;
maximum of D9-THC
25 mg/d divided B.I.D.)
Secondary: Kurtzke EDSS,
Rivermead Mobility Index,
timed 10-m walk, United
Kingdom Neurological
Disability Score, BI, General
Health Questionnaire, 9
‘‘category’’ rating scales, and
questions about overall
effect of the medication
MS/Vaney et al,11
2004
57 (Crossover) OCE (D9-THC 2.5 mg/
CBD 0.9 mg per
capsule) versus
placebo
Primary: Change in total
Ashworth Scale score
No difference in any primary
or secondary outcome in the
intention-to-treat population.
Improvements in spasm
frequency and mobility were
seen in the active
medication group after
excluding a patient who fell
in the placebo phase.
(Weight-based dosing;
maximum of D9-THC
30 mg/d divided T.I.D.)
Secondary: Numerous
CAMS Study, 12-
month follow-
up/Zajicek,12
2005
630 Continuation of CAMS
Study; see above
Primary: Change in spasticity
measured by the Ashworth
Scale
Primary outcome significant for
the dronabinol group only.
As in the original CAMS
Study, ratings of spasticity,
pain, sleep, and spasms
improved on both active
treatments versus placebo.
This study suggested that
some patient-reported
benefits may be maintained
for up to 1 year of therapy.
CAMS LUTS
Study/Freeman
et al,13 2006
630 Continuation of CAMS
Study; see above
Primary: Reduction in UIEs
based on a 3-day urinary
diary from baseline to week
13
OCE reduced UIEs by 25% (P
¼ .005) and dronabinol
reduced UIEs by 19% (P
¼ 0.039) relative to placebo.
This study suggested that
cannabinoids may have a
clinical effect on LUTS.
The MS and
Extract of
Cannabis Trial/
Zajicek et al,10
2012
279 OCE (D9-THC 2.5 mg/
CBD [range, 0.8-1.8
mg] per capsule)
versus placebo
Primary: 11-point CRS of
improvement in spasticity
where 0 ¼ very much better,
5 ¼ no change, and 10
¼ very much worse; clinically
relevant ‘‘relief of muscle
stiffness’’ ¼ 0-3
29.4% of patients in the OCE
group achieved ‘‘relief of
muscle stiffness’’ versus
15.7% in the placebo group.
Patients in the OCE group
also saw improved muscle
spasms and sleep
disturbances, absolute
measurements of body pain
and muscle stiffness, MSSS-
88 measures of muscle
stiffness, spasms, and effect
of spasticity on body
movement, and MSWS-12
total score.
(Weight-based dosing;
maximum of D9-THC
25 mg/d divided B.I.D.)
Secondary: 11-point CRS of
body pain, muscle spasms,
sleep disturbance; absolute
measures of spasticity, body
pain, muscle spasms, sleep
disturbance; MSSS-88; MS
Impact Scale-29; MSWS-12,
and the EDSS
Ment Health Clin [Internet]. 2017;7(1):29-38. DOI: 10.9740/mhc.2017.01.029 32
TABLE: Randomized trials of medical marijuana in psychiatric and neurologic disorders (continued)
Study or
Condition/Source,
y
No. of
Participants
Cannabinoid
Formulation/Dose Outcomes Results/Conclusion
Parkinson disease/
Carroll et al,14
2004
18 (Crossover) OCE (D9-THC 2.5 mg/
CBD 1.25 mg per
capsule) versus
placebo
Primary: UPDRS questions 32-
34 score sum change from
baseline to end point
Placebo performed better than
OCE as measured by UPDRS
questions 32-34 (P ¼ .09, not
significant).
(Weight-based dosing of
0.25 mg/kg D9-THC)
Parkinson disease/
Chagas et al,15
2014
21 CBD 75 mg and CBD 300
mg versus placebo
Primary: UPDRS, PDQ-39,
Udvalg for Kliniske
CBD 300 mg significantly
improved PDQ-39 total score
versus placebo (P ¼ .05).
Additionally, improvements
were also seen on 2
subscales of the PDQ-39
(ADL and stigma), both
P, .05. No differences were
realized for any other
outcome measure.
Undersøgelser side effect
rating scale
Social anxiety
disorder/Crippa
et al,16 2011
10 CBD 400 mg versus
placebo
Subjective ratings of anxiety
and side effects by VAMS
consisting of 16 items,
grouped into 4 factors (ie,
anxiety, mental sedation,
physical sedation, and
‘‘other feelings/attitudes’’)
CBD significantly reduced
VAMS scores versus placebo
on the anxiety factor at
various times throughout the
anxiety-provoking stimulus
without demonstrating
appreciable side effects.
(Head-imaging procedure was
the anxiety-provoking
stimulus)
Social anxiety
disorder/
Bergamaschi et
al,17 2011
24 CBD 600 mg versus
placebo
VAMS anxiety, sedation,
cognitive impairment, and
discomfort; SSPS-N; BSS.
The CBD group had
significantly lower scores
during the speech phase of
the SPST on VAMS anxiety,
cognitive impairment, and
discomfort. Significant
differences were also
realized on the SSPS-N in
favor of the CBD group
during the anticipation and
speech phases of the SPST.
No differences were realized
on the BSS.
(SPST was the anxiety-
provoking stimulus)
Schizophrenia/
D’Souza et al,19
2005
13 THC 2.5 mg and 5 mg
intravenously versus
placebo
Hopkins Verbal Learning Test,
distractibility and vigilance,
verbal fluency, PANSS,
feeling states,
extrapyramidal symptoms,
and effects on prolactin and
cortisol
THC significantly worsened
symptoms as measured by
all end points compared with
placebo.
Schizophrenia/
Leweke et al,20
2012
42 CBD versus amisulpride Primary: Brief Psychiatric
Rating Scale and PANSS
scores
Both treatments reduced
symptoms as measured by
the PANSS by ;30 points
from baseline. Additionally,
there was no difference in %
responders (ie, 20%
reduction in PANSS)
between either group; P
¼ 1.0. Noninferiority could
not be demonstrated.
(Both titrated to 800
mg/d)
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TABLE: Randomized trials of medical marijuana in psychiatric and neurologic disorders (continued)
Study or
Condition/Source,
y
No. of
Participants
Cannabinoid
Formulation/Dose Outcomes Results/Conclusion
Tobacco use
disorder/Morgan
et al,21 2013
24 CBD 400 lg/inhalation
versus placebo
Number of cigarettes smoked,
VAS craving measure, Tiffany
Craving Questionnaire, and
side effects using the Mood
Rating Scale
Repeated-measures analysis of
variance interaction of time
3 treatment was not
significant (P ¼ .054).
However, CBD demonstrated
a significant reduction in
number of cigarettes
smoked versus placebo from
baseline to end point.
Neuropathic pain/
Wilsey et al,22
2008
38 (Crossover) Cannabis cigarettes
(3.5% and 7% THC)
versus placebo
VAS pain intensity (0-100) Versus placebo, cannabis
cigarettes significantly
reduced pain on the VAS
(;55/100 to ;30/100, P
¼ .016).(Cumulative dose of 9‘‘puffs’’ during 2
hours)
Neuropathic pain/
Ware et al,23
2010
23 (Crossover) Cannabis smoked in a
pipe (2.5%, 6%, and
9.4% THC) versus
placebo
VAS pain intensity (0-10) Significant difference between
placebo and 9.4% THC (0.7-
point reduction on average
daily pain, P , .05). Those
using 9.4% THC cannabis
versus placebo also reported
improved ability to fall
asleep easier (P ¼ .001),
faster (P , .001), and were
drowsier (P ¼ .003).
(Smoked T.I.D. for 5
days, followed by 9-
day washouts)
Neuropathic pain/
Wilsey et al,24
2013
39 (Crossover) Vaporized cannabis
(1.29% and 3.53%
THC) versus placebo
NNT for 30% pain reduction on
VAS pain intensity
NNT ¼ 3.2 for 1.29% THC
versus placebo, NNT ¼ 2.9
for 3.53% THC versus
placebo.(Administered during 3
study visits; 8-12 puffs
per visit [self-titrated])
Neuropsychiatric
symptoms of
dementia/van
den Elsen et
al,36 2015
50 THC 1.5 mg PO T.I.D. Primary: Neuropsychiatric
Inventory
No differences in any primary
or secondary outcome,
tolerated similar to placebo.Secondary: Cohen-Mansfield
Agitation Inventory, BI,
Quality of Life–Alzheimer
Disease Scale
Huntington/
Consroe et al,37
1991
18 CBD 10 mg/kg PO daily Primary: Marsden and Quinn’s
chorea severity
Not effective for chorea,
tolerated similar to placebo.
Depression/Kotin
et al,38 1973
8 THC 0.3 mg/kg PO B.I.D. 15-point ‘‘nurse’s rating scale,’’
15-point ‘‘patient’s rating
scale’’
Did not produce significant
euphoria or an
antidepressant response.
Anorexia/Gross et
al,39 1983
11 THC (maximum 30 mg/d
PO) versus diazepam
(maximum 15 mg/d
PO)
Hopkins Symptom Checklist-
90, Goldberg Anorectic
Attitude Questionnaire,
Goldberg Situational
Discomfort Scale, Psychiatric
Rating Scale
Neither safe nor effective in
the treatment of anorexia
nervosa.
Abbreviations: D-9-THC¼D-9-tetrahydrocannabinol; BI¼Barthel Index; B.I.D.¼ two times a day; BSS¼Bodily Symptoms Scale; CAMS¼ cannabinoids
in multiple sclerosis; CBD¼ cannabidiol; CRS¼ category rating scale; EDSS¼Expanded Disability Status Scale; LUTS¼ lower urinary tract symptoms;
MS¼multiple sclerosis; MSSS-88¼MS Spasticity Scale; MSWS-12¼MS Walking Scale; NNT¼number needed to treat; OCE¼oral cannabis extract;
PANSS¼Positive and Negative Syndrome Scale; PDQ-39¼Parkinson Disease Questionnaire-39; PO¼by mouth; SPST¼Simulated Public Speaking
Test; SSPS-N¼Negative Self-Statements during Public Speaking scale; T.I.D.¼ three times a day; UIE¼urge incontinence episodes; UPDRS¼Unified
Parkinson’s Disease Rating Score; VAMS¼Visual Analogue Mood Scale; VAS¼Visual Analogue Scale.
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authors stated that there were no serious short- or long-
term adverse events associated with study participation.
The first and only randomized, double-blind, active-
controlled, noninferiority trial of OCE in schizophrenia
was conducted in Germany in 42 patients who were
randomized to receive either CBD or amisulpride (an
atypical antipsychotic, established as effective, and used
in many non-US countries) during 4 weeks.20 Only
patients with a Brief Psychiatric Rating Scale (BPRS)
score 36 and a BPRS THOT (thought disorder subscale;
ie, grandiosity, suspiciousness, hallucinatory behavior,
unusual thought content) score 12 were included.
Primary outcomes were changes in the BPRS and Positive
and Negative Symptom Scale (PANSS) scores during the
28-day treatment period. Patients were then randomized
and started on either 200 mg of amisulpride or CBD,
increasing to 800 mg/d in 4 divided doses during the first
week of the study. Results showed that patients who were
treated with amisulpride or CBD showed significant
clinical improvement as shown by PANSS total, positive,
negative, and general psychopathology score reductions
(both reduced PANSS total by ;30 points by day 28).
There was also no difference in the proportion of
responders (20% reduction in PANSS total score)
between treatment groups (CBD, 15 of 20; amisulpride,
14 of 19; P¼ 1.0); however, noninferiority was not
demonstrated (P¼.27). Additionally, CBD was associated
with fewer extrapyramidal symptoms (P¼.006), less
weight gain (P¼.010), and lower prolactin increase
(P , .001), and was well-tolerated. It is important to point
out that the lack of a placebo group in this study was a
major limitation.
Tobacco Use Disorder
A randomized, double-blind, placebo-controlled study21
was conducted in 24 cigarette smokers who were
randomized to receive either inhaled CBD (n¼ 12) or
placebo (n¼ 12) for 1 week to test the hypothesis that
CBD can reduce nicotine consumption. Cannabidiol or
placebo was delivered via a pressurized metered dose
inhaler at a dose of 400 lg per depression. Participants
were required to text the number of times they used the
inhalers per day, the number of cigarettes smoked, and
the amount of craving they were experiencing on the VAS
craving measure. Craving was also assessed using the
Tiffany Craving Questionnaire, and side effects were
assessed using the Mood Rating Scale. Repeated-mea-
sures ANOVA interaction of time3 treatment was not
significant (P¼.054). Cannabidiol demonstrated a signif-
icant reduction in cigarettes smoked (P¼.002) during 1
week, whereas placebo did not (CBD group ;90 to ;55;
placebo group ;80 to ;70 cigarettes [numbers estimated
from graph; actual numbers not provided]). No significant
differences were realized between groups on the Tiffany
Craving Questionnaire or the Mood Rating Scale.
Neuropathic Pain
One of the first high-quality trials that evaluated MM in
patients with mixed types of neuropathic pain was a
randomized, double-blind, placebo-controlled crossover
study that included 38 patients.22 The study compared
cannabis cigarettes (3.5% and 7% THC) versus placebo
cigarettes (made from the whole plant with cannabinoids
extracted). All 3 groups scored an average of about 55/100
on the VAS pain intensity scale prior to treatment. The
procedure consisted of three 6-hour experimental ses-
sions. Each experimental session was spaced out by at
least 3 days to allow for the metabolism of residual
cannabinoids. Results showed that versus placebo,
cannabis cigarettes significantly reduced pain on the
VAS (0.0035-point decrease per minute; from;55 to ;30;
P¼.016); there was a ceiling effect of both the 3.5% and
7% cigarettes over time (P¼.95). Acute cognitive effects
on memory with the high-dose cannabis cigarettes were
observed.
Another study23 investigating the use of smoked cannabis
in patients with neuropathic pain was a randomized,
double-blind, placebo-controlled crossover study that
included 23 adults with chronic neuropathic pain second-
ary to trauma or surgery. The study compared various
strengths of cannabis (0% [placebo], 2.5%, 6.0%, and
9.4% THC) smoked in a pipe 3 times a day for 5 days,
separated by a 9-day washout in the treatment of
neuropathic pain. Results showed that there was a
significant difference between 0% (placebo) and 9.4%
THC on the VAS (0.7-point reduction on average daily
pain; P , .05). Patients also reported improved ability to
fall asleep easier (P¼.001), faster (P , .001), and were
more drowsy (P¼.003) in those using 9.4% THC versus
0% (placebo). There were no differences in mood or
quality of life between various THC doses and placebo.
Most common adverse effects included headache, dry
mouth, burning sensation in the areas of the pain,
dizziness, numbness, and cough.
Another trial identified was a randomized, double-blind,
placebo-controlled, crossover study24 that included 39
patients with mixed neuropathic pain. The study com-
pared vaporized cannabis at strengths of 0% (placebo),
1.29%, and 3.53% THC during 3 study visits; patients were
allowed to self-titrate dose (8-12 puffs per visit). In this
study the authors calculated number needed to treat for
30% pain reduction for the various strengths of cannabis.
Results showed that the number needed to treat was 3.2
for low-dose (1.29% THC) versus placebo and 2.9 for
medium-dose (3.53% THC) versus placebo. Notably, the
number needed to treat for 50% pain reduction for first-
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line medications ranges from 3.6 (TCAs) to 7.7 (pregaba-
lin).25
Discussion
The American Academy of Neurology (AAN) published a
systematic review26 and has issued a position statement27
regarding the use of MM in selected neurologic disorders.
The AAN position statement outlines that the legislation
around MM is ‘‘not supported by high-level medical
research.’’ Additionally, the position statement outlines
the fact that long-term safety data are unavailable;
however, it also calls for reclassification of marijuana from
a Schedule I (C-I) controlled substance so that more rigorous
research may be conducted. The American Psychiatric
Association has also issued a position statement28 that does
not seem to hold the same tone as the AAN’s position
statement. The statement outlines that, ‘‘There is currently
no scientific evidence to support the use of marijuana as an
effective treatment for any psychiatric illness’’ and that
‘‘several studies have shown that cannabis use may in fact
exacerbate or hasten the onset of psychiatric illnesses.’’ The
latter of these two statements refers to systematic reviews
and meta-analyses that have outlined the risk of psychosis
associated with marijuana use.29-31
Other potential risks, according to the Substance Abuse
and Mental Health Services Administration Web site,32
include short-term problems with learning and memory,
distorted perception, difficulty thinking and solving
problems, and incoordination. Substance Abuse and
Mental Health Services Administration reports that
marijuana smoking also increases the risk of cancer of
the head, neck, lungs, and respiratory tract; other
publications neither refute nor support this statement.33
Other adverse effects caused by marijuana include
tachycardia, palpitations, hypertension, acute myocardial
infarction, ischemic attack, coughing, wheezing, sputum
production, lethargy, sedation, slowed reaction time,
psychologic dysfunction, and visual disturbances.34
One of the most important points to cover is related to the
differing formulations that are collectively called ‘‘medical
marijuana.’’ A big drawback of grouping all MM products
together is that they are all different regarding their
makeup in terms of THC and CBD content. Some
formulations have varying ratios of THC to CBD, other
preparations only contain THC, and still others only contain
CBD. This is vital to note because THC and CBD behave
differently pharmacologically and therapeutically, one of
the major differences being that THC produces euphoria
and intoxication, and CBD has been shown to antagonize
some of the effects of THC and has anxiolytic and
antipsychotic effects.35 That said, product selection for
the patient who uses MM is of paramount importance. This
review focused on randomized, double-blind, controlled
trials of phytocannabinoids for the treatment of these
disorders. It is important to keep an evidence-based
approach in mind, even with substances considered to be
illegal under US federal law. Clinicians must weigh the risks
and benefits of the use of MM in their patients and should
ensure that patients have tried other treatment modalities
with higher levels of evidence for use when available and
appropriate. In this review, studies were identified that
evaluated the use of MM in dementia, MS, PD, anorexia,
Huntington disease, schizophrenia, social anxiety disorder,
depression, tobacco use disorder, neuropsychiatric symp-
toms of dementia, and neuropathic pain. The strongest
evidence seems to be established for treatment of
symptoms of MS and neuropathic pain; however, the
International Association for the Study of Pain–Neuropathic
Pain Special Interest Group (IASP NuePSIG) guidelines have
a weak recommendation against the use of cannabinoids
based on negative results of trials reviewed and the
potential misuse, abuse, and long-term mental health risks
in susceptible individuals.25 It should be noted that most
trials reviewed in the IASP NeuPSIG guidelines compared
nabiximols to placebo; this formulation was not included in
this review. Promising areas of study that require further
research include the use of MM in social anxiety disorder
and schizophrenia: an important point being that the active
medications in these studies were formulations of pure
CBD. Data were fairly limited in Huntington disease, PD,
and tobacco use disorder, making drawing definitive
conclusions difficult. There is probably not a place in
therapy for MM in depression, anorexia, and neuropsychi-
atric symptoms of dementia.
Conclusion
‘‘Medical marijuana’’ encompasses everything from
whole-plant cannabis to synthetic cannabinoids available
for commercial use approved by regulatory agencies. In
determining whether MM is of clinical utility to our
patients, it is important to keep in mind chemical
constituents, dose, delivery, and indication. Selection of
the patient appropriate for MM must be carefully
considered because clinical guidelines and treatment
options with stronger levels of evidence should be
exhausted first in most cases. There seems to be strongest
evidence for the use of MM in patients with MS and in
patients with neuropathic pain; moderate evidence exists
to support further research in social anxiety disorder,
schizophrenia, PD, and tobacco use disorder; evidence is
limited for use in patients with dementia, Huntington
disease, depression, and anorexia. Future research for the
use of MM in other psychiatric and neurologic diseases
includes posttraumatic stress disorder, Tourette syndrome,
and epilepsy, because there were some studies identified
that did not meet inclusion criteria for this review.
Ment Health Clin [Internet]. 2017;7(1):29-38. DOI: 10.9740/mhc.2017.01.029 36
References
1. Hill KP. Medical marijuana for treatment of chronic pain and
other medical and psychiatric problems: a clinical review. JAMA.
2015;313(24):2474-83. DOI: 10.1001/jama.2015.6199. PubMed
PMID: 26103031.
2. New York State Medical Marijuana Program. About the medical
marijuana program [Internet]. Albany (NY): New York State
Department of Health Website [revised 2016 Apr; cited 2016
May 16]. Available from: https://www.health.ny.gov/regulations/
medical_marijuana/about.htm
3. Huestis MA. Human cannabinoid pharmacokinetics. Chem
Biodivers. 2007;4(8):1770-804. DOI: 10.1002/cbdv.200790152.
PubMed PMID: 17712819.
4. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S,
Hernandez AV, et al. Cannabinoids for medical use: a systematic
review and meta-analysis. JAMA. 2015;313(24):2456-73. DOI: 10.
1001/jama.2015.6358. PubMed PMID: 26103030.
5. Petro DJ, Ellenberger C Jr. Treatment of human spasticity with
delta 9-tetrahydrocannabinol. J Clin Pharmacol. 1981;21(8-9
Suppl):413S-6S. PubMed PMID: 6271839.
6. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW.
Delta-9-THC in the treatment of spasticity associated with
multiple sclerosis. Adv Alcohol Subst Abus. 1988;7(1):39-50. DOI:
10.1300/J251v07n01_04. PubMed PMID: 2831701.
7. Greenberg HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ,
Domino EF. Short-term effects of smoking marijuana on balance
in patients with multiple sclerosis and normal volunteers. Clin
Pharmacol Ther. 1994;55(3):324-8. DOI: 10.1038/clpt.1994.33.
PubMed PMID: 8143398.
8. Killestein J, Hoogervorst ELJ, Reif M, Kalkers NF, van Loenen AC,
Staats PGM, et al. Safety, tolerability, and efficacy of orally
administered cannabinoids in MS. Neurology. 2002;58(9):1404-7.
DOI: 10.1212/WNL.58.9.1404. PubMed PMID: 12011290.
9. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al.
Cannabinoids for treatment of spasticity and other symptoms
related to multiple sclerosis (CAMS study): multicentre rando-
mised placebo-controlled trial. Lancet. 2003;362(9395):1517-26.
DOI: 10.1016/S0140-6736(03)14738-1. PubMed PMID: 14615106.
10. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B,
Hagen U, et al. Efficacy, safety and tolerability of an orally
administered cannabis extract in the treatment of spasticity in
patients with multiple sclerosis: a randomized, double-blind,
placebo-controlled, crossover study. Mult Scler. 2004;10(4):417-
24. DOI: 10.1191/1352458504ms1048oa. PubMed PMID:
15327040.
11. Zajicek JP. Cannabinoids in multiple sclerosis (CAMS) study:
safety and efficacy data for 12 months follow up. J Neurol
Neurosurg Psychiatry. 2005;76(12):1664-9. DOI: 10.1136/jnnp.
2005.070136. PubMed PMID: 16291891.
12. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE,
Wright D, Zajicek J. The effect of cannabis on urge incontinence
in patients with multiple sclerosis: a multicentre, randomised
placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic
Floor Dysfunct. 2006;17(6):636-41. DOI: 10.1007/s00192-006-
0086-x. PubMed PMID: 16552618.
13. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG. Multiple
sclerosis and extract of cannabis: results of the MUSEC trial. J
Neurol Neurosurg Psychiatry. 2012;83(11):1125-32. DOI: 10.1136/
jnnp-2012-302468. PubMed PMID: 22791906.
14. Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, et al.
Cannabis for dyskinesia in Parkinson disease: a randomized
double-blind crossover study. Neurology. 2004;63(7):1245-50.
PubMed PMID: 15477546.
15. Chagas MH, Zuardi AW, Tumas V, et al. Effects of cannabidiol in
the treatment of patients with Parkinson’s disease: an
exploratory double-blind trial. J Psychopharmacol. 2014;28(11):
1088-98. DOI: 10.1177/0269881114550355. PubMed PMID:
25237116.
16. Crippa JAS, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran
FLS, Martin-Santos R, et al. Neural basis of anxiolytic effects of
cannabidiol (CBD) in generalized social anxiety disorder: a
preliminary report. J Psychopharmacol. 2011;25(1):121-30. DOI:
10.1177/0269881110379283. PubMed PMID: 20829306.
17. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De
Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety
induced by simulated public speaking in treatment-naı¨ve social
phobia patients. Neuropsychopharmacology. 2011;36(6):1219-
26. DOI: 10.1038/npp.2011.6. PubMed PMID: 21307846.
18. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of
cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):
1037-43. DOI: 10.1007/s11064-005-6978-1. PubMed PMID:
16258853.
19. D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K,
Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects
in schizophrenia: implications for cognition, psychosis, and
addiction. Biol Psychiatry. 2005;57(6):594-608. DOI: 10.1016/j.
biopsych.2004.12.006. PubMed PMID: 15780846.
20. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C,
et al. Cannabidiol enhances anandamide signaling and alleviates
psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:
e94. DOI: 10.1038/tp.2012.15. PubMed PMID: 22832859.
21. Morgan CJA, Das RK, Joye A, Curran HV, Kamboj SK.
Cannabidiol reduces cigarette consumption in tobacco smokers:
preliminary findings. Addict Behav. 2013;38(9):2433-6. DOI: 10.
1016/j.addbeh.2013.03.011. PubMed PMID: 23685330.
22. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux
B, et al. A randomized, placebo-controlled, crossover trial of
cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506-
21. DOI: 10.1016/j.jpain.2007.12.010. PubMed PMID: 18403272.
23. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T,
et al. Smoked cannabis for chronic neuropathic pain: a
randomized controlled trial. CMAJ. 2010;182(14):E694-701.
DOI: 10.1503/cmaj.091414. PubMed PMID: 20805210.
24. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H.
Low-dose vaporized cannabis significantly improves neuropathic
pain. J Pain. 2013;14(2):136-48. DOI: 10.1016/j.jpain.2012.10.009.
PubMed PMID: 23237736.
25. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R,
Dworkin RH, et al. Pharmacotherapy for neuropathic pain in
adults: a systematic review and meta-analysis. Lancet Neurol.
2015;14(2):162-73. DOI: 10.1016/S1474-4422(14 )70251-0.
PubMed PMID: 25575710.
26. Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G,
et al. Systematic review: efficacy and safety of medical
marijuana in selected neurologic disorders: report of the
Guideline Development Subcommittee of the American Acad-
emy of Neurology. Neurology. 2014;82(17):1556-63. DOI: 10.
1212/WNL.0000000000000363. PubMed PMID: 24778283.
27. Patel A, Fee D, Brust JCM, Song S, Miller TR, Narayanaswami P.
American Academy of Neurology Position Statement: use of
medical marijuana for neurologic disorders [Internet]. Minneap-
olis (MN): American Academy of Neurology [cited 2016 Sept 25].
Available from: https://www.aan.com/uploadedFiles/Website_
Library_Assets/Documents/6.Public_Policy/1.Stay_Informed/2.
Position_Statements/3.PDFs_of_all_Position_Statements/Final%
20Medical%20Marijuana%20Position%20Statement.pdf
28. Zaman T, Rosenthal RN, Renner JA Jr, Kleber HD, Milin R.
Resource document on marijuana as medicine, 2013 [Internet].
Washington: American Psychiatric Association [cited 2016 Sept
25]. Available at: https://www.psychiatry.org/File%20Library/
Psychiatrists/Directories/Library-and-Archive/resource_
documents/rd2013_MarijuanaMedicine.pdf
Ment Health Clin [Internet]. 2017;7(1):29-38. DOI: 10.9740/mhc.2017.01.029 37
29. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor
for psychosis: systematic review. J Psychopharmacol. 2005;
19(2):187-94. PubMed PMID: 15871146.
30. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones
PB, Burke M, et al. Cannabis use and risk of psychotic or
affective mental health outcomes: a systematic review. Lancet.
2007;370(9584):319-28. DOI: 10.1016/S0140-6736(07)61162-3.
PubMed PMID: 17662880.
31. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis
use and earlier onset of psychosis: a systematic meta-analysis.
Arch Gen Psychiatry. 2011;68(6 ):555-61. DOI: 10.1001/
archgenpsychiatry.2011.5. PubMed PMID: 21300939.
32. Cannabis [Internet]. Rockville (MD): Substance Abuse and
Mental Health Services Administration [revised 2015 Oct; cited
2016 May 16]. Available from: http://www.samhsa.gov/atod/
cannabis
33. Huang YHJ, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M.
An epidemiologic review of marijuana and cancer: an update.
Cancer Epidemiol Biomarkers Prev. 2015;24(1):15-31. DOI: 10.
1158/1055-9965.EPI-14-1026. PubMed PMID: 25587109.
34. Seamon MJ, Fass JA, Maniscalco-Feichtl M, Abu-Shraie NA.
Medical marijuana and the developing role of the pharmacist.
Am J Health Syst Pharm. 2007;64(10):1037-44. DOI: 10.2146/
ajhp060471. PubMed PMID: 17494903.
35. McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are
cannabidiol and D(9) -tetrahydrocannabivarin negative modula-
tors of the endocannabinoid system?: a systematic review. Br J
Pharmacol. 2015;172(3):737-53. DOI: 10.1111/bph.12944. PubMed
PMID: 25257544.
36. van den Elsen GA, Ahmed AI, Verkes RJ, Kramers C, Feuth T,
Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric
symptoms in dementia: a randomized controlled trial. Neurology.
2015;84(23):2338-46. DOI: 10.1212/WNL.0000000000001675.
PubMed PMID: 25972490.
37. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et
al. Controlled clinical trial of cannabidiol in Huntington’s disease.
Pharmacol Biochem Behav. 1991;40(3):701-8. PubMed PMID:
1839644.
38. Kotin J, Post RM, Goodwin FK. 9 -Tetrahydrocannabinol in
depressed patients. Arch Gen Psychiatry. 1973;28(3):345-8.
PubMed PMID: 4569675.
39. Gross H, Ebert MH, Faden VB, Goldberg SC, Kaye WH, Caine ED,
et al. A double-blind trial of delta 9-tetrahydrocannabinol in
primary anorexia nervosa. J Clin Psychopharmacol. 1983;3(3):
165-71. PubMed PMID: 6308069.
Ment Health Clin [Internet]. 2017;7(1):29-38. DOI: 10.9740/mhc.2017.01.029 38
